Scott Eisenberg, DO
Cardiovascular Disease · Eatontown, NJNPI 1891778353
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $111,750 of the $131,739 with a category attached, or 84.8%. 49 manufacturers reported payments, led by Johnson & Johnson at 51.9% of the total. Reporting peaked in 2020 at $36,625 and has fallen 92.9% since, to $2,614 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 979 payments — averaging $134.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$68K
- AstraZeneca$46K
- Novartis$4K
- Esperion Therapeutics, Inc.$2K
- Actelion Pharmaceuticals US, Inc.$2K
- Boston Scientific$1K
- plus $8K from 43 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$111,75085%
- Travel & lodging$9691%
- Food & beverage$18,31514%
- Education$4040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$67,125
- FARXIGA$43,980
- ENTRESTO$2,650
- NEXLIZET$2,125
- NEXLETOL$2,125
- WATCHMAN FLX$231
- LEQVIO$212
- RotarexS 6 F x 135 cm$161
- WATCHMAN Access System$148
- BRILINTA$114
- AVVIGO Guidance System$106
- General - CRM_CRM$103
- Micra$103
How this compares
$131,739 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 44 | $564,123 |
| UptraviSelexipag | 36 | $441,228 |
| XareltoRivaroxaban | 282 | $332,482 |
| EliquisApixaban | 162 | $187,808 |
| Repatha SureclickEvolocumab | 164 | $177,057 |
| EntrestoSacubitril/Valsartan | 96 | $116,328 |
| FarxigaDapagliflozin Propanediol | 94 | $82,446 |
| OzempicSemaglutide | 44 | $54,961 |
| Praluent PenAlirocumab | 41 | $45,481 |
| MultaqDronedarone Hcl | 34 | $40,103 |
| JardianceEmpagliflozin | 36 | $33,925 |
| JanuviaSitagliptin Phosphate | 34 | $29,748 |
| BrilintaTicagrelor | 27 | $28,530 |
| Icosapent Ethyl | 23 | $15,166 |
| VascepaIcosapent Ethyl | 23 | $14,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,822 | $1,005,35180 claims |
| Johnson & JohnsonXarelto | $68,392 | $332,482282 claims |
| PfizerEliquis | $285 | $187,808162 claims |
| NovartisEntresto | $4,443 | $116,32896 claims |
| AstraZenecaFarxiga, Brilinta | $45,595 | $110,976121 claims |
| Novo NordiskOzempic | $135 | $54,96144 claims |
| Sanofi-aventis U.S. LLCMultaq | $255 | $40,10334 claims |
| Boehringer IngelheimJardiance, Pradaxa | $544 | $39,29663 claims |
| MerckJanuvia, Janumet | $494 | $35,32345 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $297 | $10,80618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Eatontown
- L Steven ZukermanEatontown$41K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.